课题基金 / 基金详情

项目摘要

项目成果

Michael Stephen Glickman的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): CD4 T cells provide immune defense against Mycobacterium tuberculosis infection. Control of M. tuberculosis infection also requires TNF, IFN-?, iNOS and TLR-mediated innate immune signals. CD4 T cells orchestrate cellular and cytokine-mediated effector mechanisms that inhibit M. tuberculosis growth in the mammalian host. Vaccine induced priming of long-term memory CD4 T cells specific for M. tuberculosis, therefore, is an important but, to date, incompletely met goal. The proposed experiments focus on an important question: Why are CD4 T cells induced by natural infection unable to eliminate M. tuberculosis from the host. We hypothesize that natural infection primes mixed populations of effector and regulatory CD4 T cells that restrict M. tuberculosis growth but do not lead to sterile immunity. To test this hypothesis, we generated T cell receptor transgenic mice specific for ESAT-6, an immunodominant M. tuberculosis antigen, and tracked ESAT-6 specific CD4 T cells during infection. Adoptively transferred, Th1 differentiated ESAT-6 specific CD4 T cells provide protection against aerosol infection, enabling mechanistic studies of CD4 T cell mediated protective immunity. Our first aim is to investigate the kinetics of clonal CD4 T cell activation, expansion and contraction at different times during the course of TB infection. These studies will determine whether the inability of clear M. tuberculosis infection results from too few specific T lymphocytes, attrition of specific T cells or loss of T cell effector functions during chronic infection. Our second aim is to determine which CD4 T cell effector functions are required for protective immunity. These experiments will determine whether IFN-3 and/or TNF production by TB-specific CD4 T cells are essential for protection, and will determine the impact of innate immune responses on activation and differentiation of ESAT-6-specific T cells. Our final aim is to identify approaches that optimize in vivo, CD4 T cell-mediated protection. We will induce migration of CD4 T cells to lung parenchyma and airways, optimize in vivo differentiation of ESAT-6 specific CD4 T cells and determine the contribution of Th17 CD4 T cells to protective immunity. These studies will provide unprecedented views of CD4 T cell responses to M. tuberculosis infection and will likely suggest new and practical approaches to optimize immunity against this pathogen.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1371/journal.ppat.1002052
发表时间: 2011-05
期刊: PLoS pathogens
影响因子: 6.7
作者: [Gallegos AM, van Heijst JW, Samstein M, Su X, Pamer EG, Glickman MS]
通讯作者: Glickman MS
Rip1 controlled stress resistance and virulence in Mycobacterium tuberculosis
  • 批准号:
    10547809
  • 项目类别:
  • 资助金额:
    $46.33万
  • 财政年份:
    2019
  • 负责人:
    Michael Stephen Glickman
  • 依托单位:
Rip1 controlled stress resistance and virulence in Mycobacterium tuberculosis
  • 批准号:
    10338102
  • 项目类别:
  • 资助金额:
    $46.33万
  • 财政年份:
    2019
  • 负责人:
    Michael Stephen Glickman
  • 依托单位:
Rip1 controlled stress resistance and virulence in Mycobacterium tuberculosis
  • 批准号:
    10084263
  • 项目类别:
  • 资助金额:
    $46.33万
  • 财政年份:
    2019
  • 负责人:
    Michael Stephen Glickman
  • 依托单位:
RP-4: Immunologic Predictors of BCG Immunotherapy for Bladder Cancer
  • 批准号:
    10453636
  • 项目类别:
  • 资助金额:
    $34.33万
  • 财政年份:
    2018
  • 负责人:
    Michael Stephen Glickman
  • 依托单位:
海外基金